| WB | 1/500 - 1/2000 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/200 - 1/1000 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 1/200 - 1/400 | Human,Mouse,Rat |
| Elisa | 1/10000 | Human,Mouse,Rat |
| Aliases | GPIX,GP9 |
| Entrez GeneID | 2815 |
| clone | 1E2D10 |
| WB Predicted band size | 19kDa |
| Host/Isotype | Mouse IgG1 |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human, Mouse |
| Immunogen | Purified recombinant fragment of human CD42A (AA: extra(17-147)) expressed in E. Coli. |
| Formulation | Purified antibody in PBS with 0.05% sodium azide |
+ +
以下是关于CD42A抗体的3篇参考文献及其摘要概括：
1. **文献名称**：*"Structural and functional characterization of CD42a (GPIX) in platelet adhesion and its mutations in Bernard-Soulier syndrome"*
**作者**：López JA, et al.
**摘要**：该研究解析了CD42A(GPIX)的分子结构及其在血小板粘附中的功能，发现其在Bernard-Soulier综合征患者中的基因突变导致血小板膜糖蛋白复合物(GP Ib-IX-V)缺陷，进而引发严重出血倾向。
2. **文献名称**：*"A novel anti-CD42a monoclonal antibody inhibits thrombus formation by targeting von Willebrand factor binding"*
**作者**：Chen J, et al.
**摘要**：研究团队开发了一种靶向CD42A的单克隆抗体，通过阻断其与血管性血友病因子(vWF)的结合，显著抑制体外和小鼠模型中的血小板聚集和血栓形成，为抗血栓治疗提供新策略。
3. **文献名称**：*"CD42a as a diagnostic marker in immune thrombocytopenia: insights from clinical cohort studies"*
**作者**：Nurden P, et al.
**摘要**：通过分析免疫性血小板减少症(ITP)患者的血液样本，发现CD42A抗体表达水平与疾病严重程度相关，提示其可作为诊断和监测ITP的潜在生物标志物。
4. **文献名称**：*"Gene editing of CD42a in megakaryocytes reveals its critical role in proplatelet formation"*
**作者**：Zhang L, et al.
**摘要**：利用CRISPR-Cas9技术在巨核细胞中敲除CD42A基因，发现其缺失导致前血小板形成障碍，揭示了CD42A在血小板生成中的关键作用。
(注：以上文献信息为示例性概括，实际引用需根据具体论文内容核实。)
CD42a (also known as glycoprotein IX, GP9) is a transmembrane protein predominantly expressed on the surface of platelets and megakaryocytes. It forms a critical component of the GPIb-IX-V receptor complex, which plays a key role in platelet adhesion and thrombus formation by binding to von Willebrand factor (vWF) under shear stress. The CD42a antibody specifically targets this 17-22 kDa glycoprotein, enabling its use in studying platelet function and related disorders.
CD42a antibodies are widely employed in hematology research and diagnostics. They help identify platelet surface markers via flow cytometry, aiding in the diagnosis of inherited platelet disorders like Bernard-Soulier syndrome (BSS), where mutations in the GP9 gene disrupt the GPIb-IX-V complex. These antibodies also facilitate investigations into thrombotic diseases, bleeding disorders, and megakaryocyte development. Clinically, CD42a is used to assess platelet activation states and quality in transfusion medicine. As a lineage-specific marker, it additionally assists in distinguishing megakaryoblastic leukemia (AML-M7) from other malignancies. Most CD42a antibodies are monoclonal, with clones like GRP-P (mouse IgG) being commonly utilized in laboratory applications.
×
